(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Monday.

----------

Main Market small-cap winners

----------

Centaur Media PLC, up 23% at 16.00 pence

Quantum Data Energy PLC, up 20% at 2.30p

Kosmos Energy Ltd, up 16% at 193.75p, energy stocks rise with Brent

Mila Resources PLC, up 14% at 1.23p

Digital 9 Infrastructure PLC, up 9.1% at 4.91p, redeems 323 million shares

----------

Main Market small-cap losers

----------

PYX Resources Ltd, down 19% at 0.25p

Supply@Me Capital PLC, down 17% at 0.0025p

LMS Capital PLC, down 13% at 16.35p

DeFi Development Corp UK PLC, down 9.6% at 37.50p

Iconic Labs PLC, down 9.4% at 1.45p

----------

AIM winners

----------

Pacific Global Holdings PLC, up 16% at 1.45p

Kropz PLC, up 15% at 1.50p, notes "record" Elandsfontein March production

Seeen PLC, up 14% at 4.00p

Advanced Medical Solutions Group PLC, up 14% at 260.25p, confirms TA Associates bid approach

Abingdon Health PLC, up 14% at 10.25p

----------

AIM losers

----------

Feedback PLC, down 22% at 11.25p, faces NHS contract delay

Caledonian Holdings PLC, down 20% at 0.0033p

Kazera Global PLC, down 17% at 1.00p

Great Western Mining Corp, down 11% at 2.95p, lower gold price

Premier African Minerals Ltd, down 11% at 0.02p

----------

Small-cap and AIM movers in focus:

----------

Kosmos Energy Ltd, up 16% at 193.75p, 12-month range 0.84p-3.17p. The Dallas, Texas-based energy company rises as Brent climbs to USD94.68 a barrel from USD89.15 on Friday. Iran closed the Strait of Hormuz at the weekend, just a day after reopening it, citing the US' blockade of its ports. State broadcaster IRIB cited Iranian sources as saying "there are currently no plans to participate in the next round of Iran-US talks" in Pakistan.

----------

Solvonis Therapeutics PLC, up 9.6% at 0.31p, 12-month range 0.11p-0.40p. The biopharmaceutical company, focused on central nervous system disorders says a new executive order from US President Donald Trump is a "major and highly encouraging signal for the growing regulatory, commercial and strategic importance" of the sector in which it operates. "The executive order states that it is US policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs for serious mental illness, and includes measures relating to review prioritisation, right to try access pathways, federal-state collaboration funding, data sharing and rescheduling review following successful phase three trials," Solvonis says.

----------

Kropz PLC, up 15% at 1.50p, 12-month range 0.42p-1.80p. The Africa-focused phosphate producer and developer notes a record production month at Elandsfontein in March, as it produces 40,792 tonnes of phosphate concentrate. It says fourth-quarter production was up 11% at 115,686 tonnes. Sales for the period were 104,900 tonnes.

----------

Advanced Medical Solutions Group PLC, up 14% at 260.25p, 12-month range 168.40p-272.00p. Confirms it is in talks regarding a possible offer for the company, little more than 12 months after another potential suitor failed to secure a deal with the firm. On Saturday, Sky News reported that Boston, Massachusetts-based private equity firm, TA Associates (UK) LLP, was preparing an offer for AMS worth around 280 pence per share, or GBP600 million in total. On Monday, AMS confirmed the talks with TA Associates, but stressed there can be no certainty that a firm offer will be made, nor as to the terms on which it might be made. TA Associates is required to announce a firm intention to make an offer or that it does not intend to make an offer by May 16.

----------

Feedback PLC, down 22% at 11.25p, 12-month range 7.50p-18.00p. The London-based provider of systems for use in clinical settings says a decision from the NHS on a potential contract for Bleepa has been delayed by at least six to nine months "due to internal NHS factors". "Nevertheless, discussions have continued to progress positively with central NHS stakeholders regarding at scale opportunities for Bleepa which the board believes have the potential to be aligned to new frontline digitisation funding which is expected to become available in the 2026/27 NHS financial year," Feedback says. The firm says its cash position is being carefully managed and provides a runway to mid-2027.

----------

By Michael Hennessey, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.